DE122009000058I1
(de)
*
|
1993-09-22 |
2009-12-31 |
Jackson H M Found Military Med |
Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
|
US5849301A
(en)
*
|
1993-09-22 |
1998-12-15 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
|
US5874085A
(en)
*
|
1993-11-10 |
1999-02-23 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Vaccine for enhanced production of IgA antibodies
|
US6203794B1
(en)
*
|
1994-05-31 |
2001-03-20 |
Allergan Sales, Inc. |
Modification of clostridial toxins for use as transport proteins
|
GB9410871D0
(en)
|
1994-05-31 |
1994-07-20 |
Imperial College |
Modification of tetanus toxin for use as a transport protein
|
AU712981B2
(en)
*
|
1995-03-22 |
1999-11-18 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
|
KR100417183B1
(ko)
*
|
1995-03-22 |
2004-05-31 |
헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신 |
유기시아닐화제로활성화된가용성탄수화물을이용한면역원성구조체제조
|
JPH10504842A
(ja)
*
|
1995-06-06 |
1998-05-12 |
ヘンリー エム. ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン |
二重担体免疫原性構築物
|
ATE433329T1
(de)
|
1995-06-23 |
2009-06-15 |
Glaxosmithkline Biolog Sa |
Impfstoff bestehend aus auf aluminium-phosphat adsorbiertem, konjugiertem polysaccharid antigen
|
US6106828A
(en)
*
|
1996-02-15 |
2000-08-22 |
Novo Nordisk A/S |
Conjugation of polypeptides
|
US6309646B1
(en)
|
1996-05-09 |
2001-10-30 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates
|
US6248334B1
(en)
*
|
1997-01-08 |
2001-06-19 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
|
US6299881B1
(en)
*
|
1997-03-24 |
2001-10-09 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
|
US6750324B1
(en)
|
1997-12-02 |
2004-06-15 |
Neuralab Limited |
Humanized and chimeric N-terminal amyloid beta-antibodies
|
US6905686B1
(en)
|
1997-12-02 |
2005-06-14 |
Neuralab Limited |
Active immunization for treatment of alzheimer's disease
|
US6761888B1
(en)
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
US6787523B1
(en)
*
|
1997-12-02 |
2004-09-07 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
US7179892B2
(en)
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
US6923964B1
(en)
|
1997-12-02 |
2005-08-02 |
Neuralab Limited |
Active immunization of AScr for prion disorders
|
US6913745B1
(en)
|
1997-12-02 |
2005-07-05 |
Neuralab Limited |
Passive immunization of Alzheimer's disease
|
US6710226B1
(en)
|
1997-12-02 |
2004-03-23 |
Neuralab Limited |
Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
US7018637B2
(en)
*
|
1998-02-23 |
2006-03-28 |
Aventis Pasteur, Inc |
Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
|
US20050059802A1
(en)
*
|
1998-04-07 |
2005-03-17 |
Neuralab Ltd |
Prevention and treatment of amyloidogenic disease
|
EP1069909B1
(en)
|
1998-04-10 |
2007-06-13 |
Andrew Lees |
Conjugate vaccines for the prevention of dental caries
|
US20030147882A1
(en)
|
1998-05-21 |
2003-08-07 |
Alan Solomon |
Methods for amyloid removal using anti-amyloid antibodies
|
AU762799B2
(en)
|
1998-06-12 |
2003-07-03 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Enhancement of B cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and EBV Gp350/220
|
WO2000004922A1
(en)
*
|
1998-07-20 |
2000-02-03 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Vaccines against escherichia coli o157 infection
|
US6858211B1
(en)
*
|
1998-07-20 |
2005-02-22 |
The United States Of America As Represented By The Department Of Health And Human Services |
Vaccines against Escherichia coli O157 infection
|
US6585973B1
(en)
|
1998-10-29 |
2003-07-01 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Method for preparing solid phase conjugated vaccine
|
US6787637B1
(en)
|
1999-05-28 |
2004-09-07 |
Neuralab Limited |
N-Terminal amyloid-β antibodies
|
UA81216C2
(en)
*
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
AU5329300A
(en)
|
1999-06-10 |
2001-01-02 |
Michigan State University |
Feline calicivirus isolated from cat urine and vaccines thereof
|
WO2001015708A1
(en)
|
1999-09-02 |
2001-03-08 |
Michigan State University |
Vaccine to control equine protozoal myeloencephalitis in horses
|
US7419668B1
(en)
|
1999-09-02 |
2008-09-02 |
Board Of Trustees Of Michigan State University |
Vaccine to control equine protozoal myeloencephalitis in horses
|
CZ20022748A3
(cs)
|
2000-02-21 |
2004-03-17 |
Pharmexa A/S |
Nová metoda regulace obsahu amyloidu
|
PE20020574A1
(es)
|
2000-12-06 |
2002-07-02 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido amiloideo beta
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
US7097837B2
(en)
|
2001-02-19 |
2006-08-29 |
Pharmexa A/S |
Synthetic vaccine agents
|
IL157475A0
(en)
*
|
2001-02-20 |
2004-03-28 |
Pharmexa As |
Synthetic vaccines comprising polyhydroxypolymer carriers
|
US20030138434A1
(en)
*
|
2001-08-13 |
2003-07-24 |
Campbell Robert L. |
Agents for enhancing the immune response
|
MY144532A
(en)
|
2001-08-20 |
2011-09-30 |
Lundbeck & Co As H |
Novel method for down-regulation of amyloid
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
PT2255826E
(pt)
|
2002-08-02 |
2016-06-08 |
Glaxosmithkline Biologicals Sa |
Composições de vacina de neisseria compreendendo uma combinação de antigénios
|
AU2003278166B2
(en)
|
2002-11-01 |
2009-01-29 |
Glaxosmithkline Biologicals S.A. |
Immunogenic composition
|
EP1594969B1
(en)
*
|
2003-02-01 |
2015-05-20 |
Janssen Sciences Ireland UC |
Active immunization to generate antibodies to soluble a-beta
|
TWI374893B
(en)
|
2003-05-30 |
2012-10-21 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
GB0313916D0
(en)
|
2003-06-16 |
2003-07-23 |
Glaxosmithkline Biolog Sa |
Vaccine composition
|
US8574596B2
(en)
|
2003-10-02 |
2013-11-05 |
Glaxosmithkline Biologicals, S.A. |
Pertussis antigens and use thereof in vaccination
|
MY144231A
(en)
|
2003-12-17 |
2011-08-15 |
Wyeth Corp |
Aß IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME
|
UA93854C2
(ru)
*
|
2003-12-17 |
2011-03-25 |
Вайет Ллк |
Иммуногенный конъюгат и способ его получения
|
US20050169941A1
(en)
*
|
2004-01-29 |
2005-08-04 |
Andrew Lees |
Use of amino-oxy functional groups in the preparation of protein-polysaccharide conjugate vaccines
|
AR052051A1
(es)
|
2004-12-15 |
2007-02-28 |
Neuralab Ltd |
Anticuerpos ab humanizados usados en mejorar la cognicion
|
EP1838854B1
(en)
|
2004-12-15 |
2012-10-31 |
Janssen Alzheimer Immunotherapy |
Antibodies that recognize Beta Amyloid Peptide
|
GB0505518D0
(en)
*
|
2005-03-17 |
2005-04-27 |
Chiron Srl |
Combination vaccines with whole cell pertussis antigen
|
GB0505996D0
(en)
|
2005-03-23 |
2005-04-27 |
Glaxosmithkline Biolog Sa |
Fermentation process
|
CN103083657B
(zh)
|
2005-06-27 |
2016-06-08 |
葛兰素史密丝克莱恩生物有限公司 |
免疫原性组合物
|
EP1912665B1
(en)
*
|
2005-07-28 |
2011-01-26 |
Pfizer Products Inc. |
Vaccine against feline calicivirus (fcv) comprising a fcv capsid protein or an isolated fcv capsid protein comprising protein sequence seq id no: 13 or protein sequences having at least 95% identity thereto.
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
AR058707A1
(es)
|
2005-12-22 |
2008-02-20 |
Glaxosmithkline Biolog Sa |
Vacuna, procedimiento para fabricarla y su uso
|
US20090061478A1
(en)
*
|
2006-01-30 |
2009-03-05 |
Lene Have Poulsen |
High-Speed Quantification of Antigen Specific T-Cells in Whole Blood by Flow Cytometry
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
GB0700136D0
(en)
|
2007-01-04 |
2007-02-14 |
Glaxosmithkline Biolog Sa |
Process for manufacturing vaccines
|
EP2155782A2
(en)
*
|
2007-03-26 |
2010-02-24 |
Dako Denmark A/S |
Mhc peptide complexes and uses thereof in infectious diseases
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
EP2167121B1
(en)
|
2007-06-26 |
2015-09-02 |
GlaxoSmithKline Biologicals S.A. |
Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
|
WO2009003493A2
(en)
*
|
2007-07-03 |
2009-01-08 |
Dako Denmark A/S |
Mhc multimers, methods for their generation, labeling and use
|
ES2498040T3
(es)
|
2007-07-27 |
2014-09-24 |
Janssen Alzheimer Immunotherapy |
Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
|
WO2009039854A2
(en)
|
2007-09-27 |
2009-04-02 |
Dako Denmark A/S |
Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
DK2254592T3
(da)
|
2008-02-28 |
2019-09-09 |
Dako Denmark As |
MHC-multimerer til Borrelia-diagnostik og sygdom
|
US10722562B2
(en)
|
2008-07-23 |
2020-07-28 |
Immudex Aps |
Combinatorial analysis and repair
|
GB0817244D0
(en)
*
|
2008-09-20 |
2008-10-29 |
Univ Cardiff |
Use of a protein kinase inhibitor to detect immune cells, such as T cells
|
US10369204B2
(en)
|
2008-10-02 |
2019-08-06 |
Dako Denmark A/S |
Molecular vaccines for infectious disease
|
US11992518B2
(en)
|
2008-10-02 |
2024-05-28 |
Agilent Technologies, Inc. |
Molecular vaccines for infectious disease
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
US20120135037A1
(en)
|
2009-06-01 |
2012-05-31 |
Mizel Steven B |
Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
|
US8647621B2
(en)
|
2009-07-27 |
2014-02-11 |
Fina Biosolutions, Llc |
Method of producing protein-carbohydrate vaccines reduced in free carbohydrate
|
WO2011036560A2
(en)
|
2009-09-23 |
2011-03-31 |
Novartis Ag |
Glycoconjugate compositions and methods for treatment of hiv
|
GB0917647D0
(en)
|
2009-10-08 |
2009-11-25 |
Glaxosmithkline Biolog Sa |
Expression system
|
MX2012006961A
(es)
|
2009-12-17 |
2012-10-03 |
Fina Biosolutions Llc |
Reactivos quimicos para la activacion de polisacaridos en la preparacion de vacunas conjugadas.
|
GB201003924D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB201003922D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
JP2013521326A
(ja)
|
2010-03-10 |
2013-06-10 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
免疫原性組成物
|
NZ602971A
(en)
|
2010-04-23 |
2014-11-28 |
Serum Inst India Ltd |
Simple method for simultaneous removal of multiple impurities from culture supernatants to ultralow levels
|
GB201015132D0
(en)
|
2010-09-10 |
2010-10-27 |
Univ Bristol |
Vaccine composition
|
AU2012240231B2
(en)
*
|
2011-04-04 |
2017-05-25 |
University Of Iowa Research Foundation |
Methods of improving vaccine immunogenicity
|
GB201106225D0
(en)
|
2011-04-13 |
2011-05-25 |
Glaxosmithkline Biolog Sa |
Fermentation process
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
JP2016501550A
(ja)
|
2012-12-27 |
2016-01-21 |
グリコヴァキシン アーゲー |
Crm197に関する方法及び組成物
|
CA2923129C
(en)
|
2013-09-08 |
2020-06-09 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
US11708411B2
(en)
|
2013-12-20 |
2023-07-25 |
Wake Forest University Health Sciences |
Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
MX2020001138A
(es)
|
2014-01-21 |
2021-09-30 |
Pfizer |
Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos.
|
DK3096785T3
(da)
|
2014-01-21 |
2020-09-21 |
Pfizer |
Immunogene sammensætninger omfattende konjugerede kapsel-saccharid-antigener og anvendelser deraf
|
US9815886B2
(en)
|
2014-10-28 |
2017-11-14 |
Adma Biologics, Inc. |
Compositions and methods for the treatment of immunodeficiency
|
ES2945312T3
(es)
|
2015-01-15 |
2023-06-30 |
Pfizer |
Composiciones inmunogénicas para su uso en vacunas antineumocócicas
|
MX368897B
(es)
|
2015-05-04 |
2019-10-21 |
Pfizer |
Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos.
|
SI3313436T1
(sl)
|
2015-06-23 |
2021-09-30 |
Biological E Limited |
Multivalentno konjugirano pnevmokokno cepivo
|
PE20180657A1
(es)
|
2015-07-21 |
2018-04-17 |
Pfizer |
Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos
|
GB201518684D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
EP3377098A1
(en)
|
2015-11-20 |
2018-09-26 |
Pfizer Inc |
Immunogenic compositions for use in pneumococcal vaccines
|
GB201610599D0
(en)
|
2016-06-17 |
2016-08-03 |
Glaxosmithkline Biologicals Sa |
Immunogenic Composition
|
EP3269385A1
(en)
|
2016-07-12 |
2018-01-17 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Pneumococcal polysaccharide-protein conjugate composition
|
EP3474890A1
(en)
|
2016-06-22 |
2019-05-01 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften E. V. |
Pneumococcal polysaccharide-protein conjugate composition
|
WO2018027126A1
(en)
|
2016-08-05 |
2018-02-08 |
Sanofi Pasteur, Inc. |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
WO2018027123A1
(en)
|
2016-08-05 |
2018-02-08 |
Sanofi Pasteur, Inc. |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
WO2018064444A1
(en)
|
2016-09-30 |
2018-04-05 |
Biological E Limited |
Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates
|
KR102388325B1
(ko)
|
2016-10-20 |
2022-04-18 |
케이엠 바이올로직스 가부시키가이샤 |
저분자화 PRP를 사용한 Hib 컨쥬게이트 백신의 제조방법
|
US10751402B2
(en)
|
2016-11-09 |
2020-08-25 |
Pfizer Inc. |
Immunogenic compositions and uses thereof
|
DK3570879T3
(da)
|
2017-01-20 |
2022-04-11 |
Pfizer |
Immunogene sammensætninger til anvendelse i pneumokokvacciner
|
EP3576759A4
(en)
|
2017-01-31 |
2020-11-11 |
Merck Sharp & Dohme Corp. |
PROCESS FOR THE PREPARATION OF CAPSULE POLYSACCHARIDE PROTEIN CONJUGATES FROM STREPTOCOCCUS PNEUMONIAE SEROTYPE 19F
|
PE20191107A1
(es)
|
2017-01-31 |
2019-08-26 |
Pfizer |
Composiciones de neisseria meningitidis y metodos respectivos
|
US10259865B2
(en)
|
2017-03-15 |
2019-04-16 |
Adma Biologics, Inc. |
Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
|
BR112020004509A8
(pt)
|
2017-09-07 |
2023-01-31 |
Merck Sharp & Dohme |
Conjugado polissacarídeo-proteína carreadora, composição imunogênica compreendendo o mesmo e uso do referido conjugado
|
CN111683678B
(zh)
|
2017-12-06 |
2024-01-26 |
默沙东有限责任公司 |
包含肺炎链球菌多糖蛋白缀合物的组合物及其使用方法
|
GB201721582D0
(en)
|
2017-12-21 |
2018-02-07 |
Glaxosmithkline Biologicals Sa |
S aureus antigens and immunogenic compositions
|
GB201721576D0
(en)
|
2017-12-21 |
2018-02-07 |
Glaxosmithkline Biologicals Sa |
Hla antigens and glycoconjugates thereof
|
CN112673054A
(zh)
|
2018-07-19 |
2021-04-16 |
葛兰素史密丝克莱恩生物有限公司 |
用于制备干燥多糖的方法
|
CN113164581A
(zh)
|
2018-09-23 |
2021-07-23 |
生物E有限公司 |
纯化的肺炎链球菌荚膜多糖
|
WO2020121159A1
(en)
|
2018-12-12 |
2020-06-18 |
Pfizer Inc. |
Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
|
US20220054632A1
(en)
|
2018-12-12 |
2022-02-24 |
Glaxosmithkline Biologicals Sa |
Modified carrier proteins for o-linked glycosylation
|
JP7275277B2
(ja)
|
2018-12-19 |
2023-05-17 |
メルク・シャープ・アンド・ドーム・エルエルシー |
ストレプトコッカス・ニューモニエ多糖-タンパク質コンジュゲートを含む組成物およびその使用方法
|
EP3923982A1
(en)
|
2019-02-11 |
2021-12-22 |
Pfizer Inc. |
Neisseria meningitidiscompositions and methods thereof
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
EP3952906A1
(en)
|
2019-04-10 |
2022-02-16 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
EP3757217A1
(en)
|
2019-06-27 |
2020-12-30 |
GlaxoSmithKline Biologicals S.A. |
Methods for protein purification
|
AU2020323498A1
(en)
|
2019-07-31 |
2022-03-03 |
Sk Bioscience Co., Ltd. |
Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
|
EP3777884A1
(en)
|
2019-08-15 |
2021-02-17 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic composition
|
MX2022003682A
(es)
|
2019-09-27 |
2022-04-25 |
Pfizer |
Composiciones de neisseria meningitidis y metodos de las mismas.
|
MX2022010355A
(es)
|
2020-02-21 |
2022-09-21 |
Pfizer |
Purificacion de sacaridos.
|
EP3900739A1
(en)
|
2020-04-21 |
2021-10-27 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein
|
EP3919076A1
(en)
|
2020-06-02 |
2021-12-08 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Synthetic oligosaccharide vaccines against streptococcus pneumoniae with microparticle adjuvant formulations
|
EP4164681A1
(en)
|
2020-06-12 |
2023-04-19 |
GlaxoSmithKline Biologicals S.A. |
Bacterial immunization using nanoparticle vaccine
|
US20230226175A1
(en)
|
2020-06-25 |
2023-07-20 |
Glaxosmithkline Biologicals Sa |
Modified exotoxin a proteins
|
EP4203995A1
(en)
|
2020-08-26 |
2023-07-05 |
Pfizer Inc. |
Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
|
UY39428A
(es)
|
2020-09-17 |
2022-03-31 |
Janssen Pharmaceuticals Inc |
Composiciones de vacunas multivalentes y usos de las mismas
|
EP4232593A1
(en)
|
2020-10-22 |
2023-08-30 |
Pfizer Inc. |
Methods for purifying bacterial polysaccharides
|
AU2021373358A1
(en)
|
2020-11-04 |
2023-06-01 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
WO2023111826A1
(en)
|
2021-12-14 |
2023-06-22 |
Glaxosmithkline Biologicals Sa |
Bacterial immunization using qbeta hairpin nanoparticle constructs
|
WO2023118033A1
(en)
|
2021-12-22 |
2023-06-29 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
WO2024110839A2
(en)
|
2022-11-22 |
2024-05-30 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2024116096A1
(en)
|
2022-12-01 |
2024-06-06 |
Pfizer Inc. |
Pneumococcal conjugate vaccine formulations
|